Development and evaluation of a reconstitutable dry suspension containing isoniazid for flexible pediatric dosing

Oluwatoyin A. Adeleke*, Rose K. Hayeshi, Hajierah Davids

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

8 Citations (Scopus)


Tuberculosis (TB) is a major cause of childhood death. Despite the startling statistics, it is neglected globally as evidenced by treatment and clinical care schemes, mostly extrapolated from studies in adults. The objective of this study was to formulate and evaluate a reconstitutable dry suspension (RDS) containing isoniazid, a first-line anti-tubercular agent used in the treatment and prevention of TB infection in both children and adults. The RDS formulation was prepared by direct dispersion emulsification of an aqueous-lipid particulate interphase coupled with lyophilization and dry milling. The RDS appeared as a cream-white free-flowing powder with a semi-crystalline and microparticulate nature. Isoniazid release was characterized with an initial burst up to 5 minutes followed by a cumulative release of 67.88% ± 1.88% (pH 1.2), 60.18% ± 3.33% (pH 6.8), and 49.36% ± 2.83% (pH 7.4) over 2 hours. An extended release at pH 7.4 and 100% drug liberation was achieved within 300 minutes. The generated release profile best fitted the zero order kinetics (R2 = 0.976). RDS was re-dispersible and remained stable in the dried and reconstituted states over 4 months and 11 days, respectively, under common storage conditions.

Original languageEnglish
Article number286
Issue number3
Publication statusPublished - Mar 2020


  • Direct emulsification
  • Isoniazid
  • Microparticulate
  • Pediatric drug delivery
  • Polymer-lipid
  • Reconstitutable dry suspension
  • Tuberculosis


Dive into the research topics of 'Development and evaluation of a reconstitutable dry suspension containing isoniazid for flexible pediatric dosing'. Together they form a unique fingerprint.

Cite this